$5M Saved for Top 20 Global Pharma Company with Almac Supply Chain Oversight
One of the top 20 global pharmaceutical companies conducted a phase III clinical trial to compare the efficacy, safety, and tolerability of multiple doses of Investigational Medicinal Products (IMPs) with a comparator drug product for the treatment of Diabetes.
At mid-trial, they engaged Almac’s Supply Chain Management (SCM) experts to devise a new optimal drug supply strategy to prevent further stock-outs. The study was a randomised, double-blinded, parallel group trial. This was a truly global phase III trial with 44 countries participating across Europe, United States, Latin America, Asia and Africa.
Almac faced a number of significant challenges to maintain and optimise the IMP supply chain. The SCM assigned conducted a full review of historical patient event data from the Interactive Response Technology (IRT) report, and identified trend in dose titrations from patients enrolled in the study.
Almac saved the client $4.95 million per year while preventing further stock-outs.